重磅:自我扩增mRNA(‘self-amplifying’ RNA/saRNA)抗新冠疫苗ARCT-154震撼上市!saRNA可在细胞内自我倍增,也就允许初始接种剂量很小,是常规mRNA疫苗的1/10-1/6,可降低副作用;越来越多研究证明,saRNA不仅用...
Safety, tolerability and recommended phase 2 dose (RP2D) of an individualized, heterologous chimpanzee adenovirus (ChAd68) and self-amplifying mRNA (samRNA)-based neoantigen vaccine in combination with nivolumab and ipilimumab were assessed as primary endpoints in an ongoing phase 1/2 study in ...
Rapid response to emerging diseases is critical when developing a vaccine. Long RNA (mRNA and saRNA) is at the forefront of vaccine development. Benefits of saRNA saRNA vaccines can be developed in a fraction of the time it takes to develop a conventional vaccine ...
Tokyo-based Meiji Seika Pharma received approval for manufacturing and marketing its Kostaive sa-mRNA COVID-19 vaccine, the company announced in a Nov. 28 press release.The mRNA in the vaccine is designed to self-amplify when delivered into cells, which generate...
protein presented by a given virus, cancer cell, or other target; this protein is produced within host cells upon vaccination, inducing an immune response. samRNA therapeutics also include RNA encoding a replicon, which is a complex of proteins that produce further copies of the immunizing ...
The doses ranged from 0.1 micrograms to 10 micrograms of saRNA , with 87 percent of people generating antibodies to SARS-CoV-2, the virus that causes COVID-19. For comparison, the Moderna and Pfizer mRNA vaccines have dosages of 100 and 30 micrograms, respectively. ...
One technology being applied in this development is the use of self-amplifying mRNA (sa-mRNA) that allows host cells to make copies of the vaccine mRNA, increasing the amount of protein produced with lower doses of administered mRNA12,13,14,15. Preclinical studies have shown sa-mRNA vaccines...
The delivery of N-myc downstream-regulated gene 2 (NDRG2) self-amplifying mRNA via modified lipid nanoparticles as a potential treatment for drug-resistant... The protein, N-myc downstream-regulated gene 2 (NDRG2), a tumor suppressor, is significantly decreased or absent in many types of ca...
Both platforms were protective, but equivalent levels of protection were achieved using 1.25 μg sa-RNA compared to 80 μg mRNA (64-fold less material). Having determined that sa-RNA was more effective than mRNA, we tested hemagglutinin from three strains of influenza H1N1, H3N2 (X31), and...
and HIV-1. Self-amplifying RNAs have shown enhanced antigen expression at lower doses compared to conventional mRNA, suggesting this technology may improve immunization. This review will explore how self-amplifying RNAs are emerging as important vaccine candidates for infectious diseases, the advantages...